The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis

Yeoh, Aaron; Wong, Robert J.; Singal, Ashwani K.

doi:10.1016/j.cld.2023.01.009

Cited by 3 publications

(5 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examples of restrictive surgeries are Adjustable Gastric Banding and Sleeve Gastrectomy. Examples of restrictive and malabsorptive surgeries are Roux-en-Y Gastric Bypass and Biliopancreatic Diversion with Duodenal Switch ( 67 ). Restrictive surgeries induce less weight loss but at the expense of lower adverse effects as compared with malabsorptive surgeries ( 67 ).…”

Section: Management Of Adiposopathymentioning

confidence: 99%

“…Examples of restrictive and malabsorptive surgeries are Roux-en-Y Gastric Bypass and Biliopancreatic Diversion with Duodenal Switch ( 67 ). Restrictive surgeries induce less weight loss but at the expense of lower adverse effects as compared with malabsorptive surgeries ( 67 ). The effect on MASLD seems dependent on the type of surgery performed.…”

Section: Management Of Adiposopathymentioning

confidence: 99%

“…Endobarrier consists of the application of a plastic liner, 60 cm long, anchored to the duodenal bulb, which prevents duodenal absorption. Last, duodenal mucosa resurfacing consists of the hydrothermal ablation of 10 cm of the duodenal mucosa, which decreases its absorptive function ( 67 ).…”

Section: Management Of Adiposopathymentioning

confidence: 99%

See 2 more Smart Citations

MASLD treatment—a shift in the paradigm is imminent

Machado

2023

Front. Med.

View full text Add to dashboard Cite

MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss interventions are moving from lifestyle changes to bariatric surgery or endoscopy, and, more recently, to a new wave of anti-obesity drugs that can compete with bariatric surgery. Liver-targeted therapy is a necessity for those patients who already present liver fibrosis. The field is moving fast, and in the near future, we will testify to a disruptive change in MASLD treatment, similar to the paradigm-shift that occurred for hepatitis C almost one decade ago with direct antiviral agents.

show abstract

Section: Management Of Adiposopathymentioning

confidence: 99%

Section: Management Of Adiposopathymentioning

confidence: 99%

See 1 more Smart Citation

MASLD treatment—a shift in the paradigm is imminent

Machado

2023

Front. Med.

View full text Add to dashboard Cite

show abstract

“…[4] Currently, there are several treatment options for patients with obesity and MASH/MASLD ranging from pharmacotherapy to endoscopic bariatric metabolic therapies as well as bariatric surgery. [5,6] Despite the growing use of these interventions in the pretransplant population, literature is limited with regard to the impact of pharmacological and surgical interventions on weight loss in the posttransplant setting. [7,8] In this issue of Liver Transplantation, Richardson et al [9] present a study on the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in liver transplant recipients (LTRs), and Chow et al [10] reported the effectiveness of semaglutide in achieving weight loss in LTRs.…”

mentioning

confidence: 99%

“…Currently, there are several treatment options for patients with obesity and MASH/MASLD ranging from pharmacotherapy to endoscopic bariatric metabolic therapies as well as bariatric surgery 5,6 . Despite the growing use of these interventions in the pretransplant population, literature is limited with regard to the impact of pharmacological and surgical interventions on weight loss in the posttransplant setting 7,8 …”

mentioning

confidence: 99%